江启安, 巩方云, 张抒雁, 郎丰平, 赵美红. 高聚生联合顺铂心包腔内灌注治疗肺癌致心包积液的临床观察[J]. 中国肿瘤临床, 2006, 33(11): 648-650.
引用本文: 江启安, 巩方云, 张抒雁, 郎丰平, 赵美红. 高聚生联合顺铂心包腔内灌注治疗肺癌致心包积液的临床观察[J]. 中国肿瘤临床, 2006, 33(11): 648-650.
shu
Jiang Qian, Gong fangyun, Zhang shuyan, Lang Fengping, Zhao Meihong. Clinical Observation of Pericardial Effusion in Patients with Lung Cancer Treated with Injections of Highly Agglutinative Staphylococcin and Cisplatin into the Pericardial Cavity[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(11): 648-650.
Citation: Jiang Qian, Gong fangyun, Zhang shuyan, Lang Fengping, Zhao Meihong. Clinical Observation of Pericardial Effusion in Patients with Lung Cancer Treated with Injections of Highly Agglutinative Staphylococcin and Cisplatin into the Pericardial Cavity[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(11): 648-650.
shu

高聚生联合顺铂心包腔内灌注治疗肺癌致心包积液的临床观察

Clinical Observation of Pericardial Effusion in Patients with Lung Cancer Treated with Injections of Highly Agglutinative Staphylococcin and Cisplatin into the Pericardial Cavity

    摘要
  • 摘要: 目的 :观察高聚生联合顺铂心包腔内灌注治疗肺癌致心包积液的疗效。 方法 :81例患者随机分为两组,治疗组(高聚生+顺铂)45例,对照组(顺铂)36例,经中心静脉导管引流心包积液后,分别注入不同药物,再持续引流至心包积液完全消失后24小时撤管,引流10～15天。 结果 :治疗组和对照组总有效率分别为91.1%、80.6%,无显著性差异(P>0.05),完全缓解率分别为77.8%、52.8%,有显著性差异(P<0.05)。不良反应:白细胞降低分别为35.6%、72.2%,有显著性差异(P<0.01),恶心呕吐分别为40.0%、66.7%,有显著性差异(P<0.05)。 结论 :高聚生联合顺铂心包腔内灌注是治疗肺癌致心包积液有效、安全的方法。

     

    Abstract: Objective :To evaluate the efficacy of injecting highly agglutinative staphylococcin(HASL) and cisplatin into pericardial cavity of lung cancer patients with pericardial effusion. Methods :81 patients were randomized into two groups: 45 in the experimental group (HASL and Cisplatin) and36 in the control group (Cisplatin). After draining the pericardial effusion, the draining continued for anadditional 24 hours, and then the pericardial cavity was perfused. The draining lasted 10~15 days. Re-Sults :The response rate was 91.1% for the experimental group and 80.6% for the control group. Therewere no significant differences between the two groups (P>0.05). The complete remission was 77.8% forthe experimental group and 52.8% for the control group, which was statistically significantly different(P<0.05). The adverse effects were myelosuppression and nausea and vomiting, which were 35.6% and40.0% in the experimental group and 72.2% and 66.7% in the control group, respectively (P<0.01; P<0.05). Conclusion :Injecting HASL and cisplatin into the pericardial cavity may be a better way tocontrol pericardial effusion of lung cancer.

     

    • HTML全文
    • 参考文献(11)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回